Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN (Epoetin alfa) and NEUPOGEN (Filgrastim).
Share Data: As of September 30, 1999, 1,021,515,626 shares of Common Stock were outstanding. All share numbers in this report have been retroactively adjusted to reflect a two-for-one stock split approved in October 1999.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 1999 |
Nine Months Ended Sep 30, 1999 |
Nine Months Ended Sep 30, 1998 |
|---|---|---|---|
| Total Revenues | $847.2 | $2,413.2 | $1,963.2 |
| Net Income | $300.0 | $814.8 | $624.6 |
| Diluted EPS | $0.28 | $0.76 | $0.59 |
| Operating Cash Flow | N/A | $884.0 | $752.8 |
| Cash & Equivalents | $188.3 | $188.3 | $104.1 |
| Marketable Securities | $1,335.7 | $1,335.7 | $1,074.9 |
| Total Debt (Long-term + Current) | $322.7 | $322.7 | $328.7 |
Note: Total Debt includes $223.0 million in long-term debt and $99.7 million in commercial paper as of September 30, 1999.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 21% year-over-year for the nine months ended September 30, 1999 ($2,413.2 million vs. $1,963.2 million). Product sales rose 21% to $2,195.4 million.
- Profitability: Net income increased 30% to $814.8 million for the nine-month period. Operating income rose to $1,126.3 million.
- Unusual Item: A $49.0 million credit was recorded in the third quarter of 1999 related to reduced uncertainty regarding potential spillover liabilities to Johnson & Johnson (J&J) following an arbitration ruling. This significantly boosted operating income.
- Expense Increases: Research and development expenses increased 23% ($580.5 million vs. $470.9 million) and Selling, General, and Administrative (SG&A) expenses increased 22% ($450.0 million vs. $369.3 million) compared to the prior year nine-month period.
- Tax Rate: The effective tax rate increased to 31% for the nine months ended September 30, 1999, compared to 30.5% in the prior year, primarily due to caps on tax benefits for Puerto Rico operations and higher pretax income.
Guidance, Outlook, and Risks
Financial Outlook
- 1999 EPS Guidance: Management expects diluted earnings per share to be in the range of $0.95 to $0.97 (adjusted for the stock split) for the full year 1999. This excludes the $49 million legal award and Year 2000 inventory build impacts.
- Sales Growth: EPOGEN sales growth is expected to be in the mid-twenties for 1999 and mid-teens for 2000. NEUPOGEN sales growth is expected to be high single- to low double-digits for 1999 and high single digits for 2000.
- Year 2000 Impact: The company anticipates wholesalers will significantly build inventories in Q4 1999 due to Year 2000 contingency planning, followed by a drawdown in Q1 2000.
Risks and Contingencies
- Johnson & Johnson Arbitration: While Amgen won the arbitration regarding audit methodology, J&J is contesting the recovery of approximately $110 million in legal and audit costs. Amgen has not recognized a benefit for these costs due to uncertainty. Additionally, Amgen has filed a demand to terminate J&J's license rights alleging breach of contract regarding sales into Amgen's exclusive market; a trial is set for February 2001.
- Year 2000 Compliance: Amgen estimates total expenditures for Year 2000 compliance between $45 million and $50 million. Risks include potential disruptions to power, telecommunications, and third-party payor systems (e.g., HCFA/Medicare) which could affect reimbursement and operations.
- Reimbursement Policy: Potential federal budget proposals include a 10% cut in Medicare reimbursement for EPOGEN and a reduction in the reimbursement basis for NEUPOGEN, which could impact future sales.
Investor Verification Checklist
- Legal Award Sustainability: Verify the final resolution of the $49 million credit and the ongoing dispute over the $110 million in legal fees with Johnson & Johnson.
- Year 2000 Execution: Monitor the actual impact of Year 2000 contingency planning on Q4 1999 revenue and Q1 2000 drawdowns, as well as any operational disruptions.
- Reimbursement Changes: Track the outcome of the Clinton administration's proposed Medicare cost savings plan regarding EPOGEN and NEUPOGEN reimbursement rates.
- Stock Repurchase Program: Confirm the execution of the newly authorized $2 billion stock repurchase program approved in October 1999.
- Product Growth Rates: Validate if EPOGEN and NEUPOGEN sales growth aligns with the "mid-twenties" and "high single-digit" guidance provided, excluding inventory distortions.